Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Top 12 Gene Therapies for Eye Diseases and Blindness
In a groundbreaking era of medical research, scientists and clinicians are spearheading novel gene therapies that hold promise for transforming the landscape of eye disease treatment. These cutting-edge interventions address a spectrum of conditions ranging from Usher Syndrome and retinoschisis…
2023 Recap: Top 15 Ophthalmic Medical Devices
In a groundbreaking year for ophthalmic advancements, 2023 has witnessed the launch of cutting-edge medical devices that promise to reshape the landscape of eye care. From augmented reality headsets to innovative surgical systems, the field is experiencing a wave of…
GRF Allocates $2.5M Grant for Glaucoma Research
The Glaucoma Research Foundation (GRF) announced an unprecedented $2.5 million allocation in annual research grants, marking the most significant investment in its 46-year history dedicated to pioneering efforts towards treating glaucoma and vision loss. Understanding Glaucoma and Its Impact Glaucoma…
AI Detects Retinopathy of Prematurity with 100% Accuracy
In a study published in JAMA Ophthalmology, researchers from Oregon Health & Science University (OHSU) alongside international collaborators have unveiled an artificial intelligence (AI) technology capable of independently detecting all severe cases of a condition leading to blindness in prematurely…
MediPrint Finalizes Glaucoma Contact Lens Study
MediPrint Ophthalmics has successfully completed its SIGHT-2 phase 2b study, showcasing the efficacy of its innovative product, LL-BMT1, against a control group using bimatoprost 0.01% ophthalmic solution. LL-BMT1, a preservative-free, weekly drug-eluting contact lens, utilizes the company’s 3D printing technology,…
Vital Tears Names Joseph Tauber, MD as CMO
Vital Tears, known for its innovative autologous serum tears, is excited to announce the appointment of Joseph Tauber, MD, to the role of Chief Medical Officer (CMO). This strategic addition aims to fortify the company’s commitment to leading-edge research, physician…
Sandoz Finalizes Acquisition of Cimerli from Coherus
Sandoz has successfully completed the acquisition of the United States biosimilar, Cimerli (ranibizumab-eqrn), from Coherus BioSciences. This strategic move underscores Sandoz’s commitment to expanding its portfolio in the biopharmaceutical sector, particularly in the area of biosimilars. The transaction, initially announced…
10 Signs to Consider Glasses or New Prescriptions
Vision is a critical aspect of our daily lives, enabling us to navigate our environment, engage in activities, and enjoy the beauty of the world around us. However, our eyesight can change over time, often gradually enough that we might…
Pediatric Cataract Surgery Restores Vision for Infant
Nethradhama Super Speciality Eye Hospitals achieved a remarkable feat in pediatric eye care with the successful completion of a high-risk paediatric cataract surgery on an 8-month-old baby in Bangalore. Led by Dr. Sri Ganesh, a distinguished eye surgeon and the…
Glaukos’ iDose TR Hits the Commercial Market
Glaukos Corporation’s iDose TR, using Celanese’s VitalDose EVA (Ethylene Vinyl Acetate), to provide sustained drug release for the treatment of glaucoma has officially entered the commercial market. Having received FDA approval in December, iDose TR represents a notable departure from…